Death following COVID-19 vaccination: A case report

Abstract

Vaccines are necessary to reduce the mortality and morbidity of infectious diseases. It has played a vital role in the ongoing coronavirus disease 2019 (COVID-19) pandemic. Different types of vaccines have been developed to combat the pandemic. Adverse events following immunization including anaphylaxis have been reported for all types of COVID-19 vaccine. Anaphylaxis is common in a person who has a history of allergic reactions. Adverse reactions develop within minutes or a few hours after vaccination. Thus, in India, vaccine recipients are made to stay in the medical facility for 30 min for observation.

Herein, we report the case of a 23-year-old woman who succumbed after 24 hours of taking COVISHIELD ChAdOx1 nCoV-19 Corona Virus Vaccine (recombinant). She did not have any symptoms after vaccination during her observation at the medical facility and did not have a history of allergic reactions. She was brought dead to M.S. Ramaiah Hospital, and the autopsy revealed pulmonary edema. Antibodies to COVID-19, inflammatory markers, serum IgE, and coagulation indicators in the postmortem blood sample were high. The cause of death was attributed to a delayed allergic reaction to COVISHIELD vaccine. Newer vaccines can cause fatal allergic reaction, sometimes later than expected, even when cutaneous reactions may not be present.

Keywords

vaccine / COVID-19 / adverse reactions / death / case report

References

[1] Johns Hopkins University & Medicine [Internet]. Coronavirus Resource Center. World Countries India [03.05.2022]. Available from: https://coronavirus.jhu.edu/region/india. Accessed: 15.11.2023.

[2] Johns Hopkins University & Medicine [интернет]. Coronavirus Resource Center. World Countries India [03.05.2022]. Режим доступа: https://coronavirus.jhu.edu/region/india. Дата обращения: 15.11.2023.

[3] Johns Hopkins University & Medicine [Internet]. Coronavirus Resource Center. World Countries India [03.05.2022]. Available from: https://coronavirus.jhu.edu/region/india. Accessed: 15.11.2023.

[4] Alhumaid S, Al Mutair A, Al Alawi Z, et al. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: A systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2021;17(1):109. doi: 10.1186/s13223-021-00613-7

[5] Alhumaid S., Al Mutair A., Al Alawi Z., et al. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: A systematic review and meta-analysis // Allergy Asthma Clin Immunol. 2021. Vol. 17, N 1. P. 109. doi: 10.1186/s13223-021-00613-7

[6] Alhumaid S, Al Mutair A, Al Alawi Z, et al. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: A systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2021;17(1):109. doi: 10.1186/s13223-021-00613-7

[7] BD-GOV.COM [05.03.2022]. Available from: https://bd-gov.com/cowin-gov-in-vaccination-certificate/. Accessed: 15.11.2023.

[8] BD-GOV.COM [05.03.2022]. Режим доступа: https://bd-gov.com/cowin-gov-in-vaccination-certificate/. Дата обращения: 15.11.2023.

[9] BD-GOV.COM [05.03.2022]. Available from: https://bd-gov.com/cowin-gov-in-vaccination-certificate/. Accessed: 15.11.2023.

[10] The Times of India [Internet]. 2k serious cases of AEFI, 0.004% of 123 crore of shots given [05.03.2022]. Available from: https://timesofindia.indiatimes.com/india/2k-serious-cases-of-aefi-0-004-of-123-crore-of-shots-given-government/articleshow/88153594.cms. Accessed: 15.11.2023.

[11] The Times of India [интернет]. 2k serious cases of AEFI, 0.004% of 123 crore of shots given [05.03.2022]. Режим доступа: https://timesofindia.indiatimes.com/india/2k-serious-cases-of-aefi-0-004-of-123-crore-of-shots-given-government/articleshow/88153594.cms. Дата обращения: 15.11.2023.

[12] The Times of India [Internet]. 2k serious cases of AEFI, 0.004% of 123 crore of shots given [05.03.2022]. Available from: https://timesofindia.indiatimes.com/india/2k-serious-cases-of-aefi-0-004-of-123-crore-of-shots-given-government/articleshow/88153594.cms. Accessed: 15.11.2023.

[13] CNN-News18 [Internet]. 26k Adverse Events, 488 Deaths Reported in India During Covid Vaccination Drive [05.03.2022]. Available from: https://www.news18.com/news/india/26k-adverse-events-488-deaths-reported-in-india-during-covid-vaccination-drive-data-3845363.html. Accessed: 15.11.2023.

[14] CNN-News18 [интернет]. 26k Adverse Events, 488 Deaths Reported in India During Covid Vaccination Drive [05.03.2022]. Режим доступа: https://www.news18.com/news/india/26k-adverse-events-488-deaths-reported-in-india-during-covid-vaccination-drive-data-3845363.html. Дата обращения: 15.11.2023.

[15] CNN-News18 [Internet]. 26k Adverse Events, 488 Deaths Reported in India During Covid Vaccination Drive [05.03.2022]. Available from: https://www.news18.com/news/india/26k-adverse-events-488-deaths-reported-in-india-during-covid-vaccination-drive-data-3845363.html. Accessed: 15.11.2023.

[16] Kelso JM. Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines. Vaccine. 2021;39(6):865–867. doi: 10.1016/j.vaccine.2020.12.084

[17] Kelso J.M. Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines // Vaccine. 2021. Vol. 39, N 6. P. 865–867. doi: 10.1016/j.vaccine.2020.12.084

[18] Kelso JM. Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines. Vaccine. 2021;39(6):865–867. doi: 10.1016/j.vaccine.2020.12.084

[19] CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine: United States, December 14–23, 2020. Morb Mortal Wkly Rep. 2021;70(2):46–51. doi: 10.15585/mmwr.mm7002e1

[20] CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 Vaccine: United States, December 14–23, 2020 // Morb Mortal Wkly Rep. 2021. Vol. 70, N 2. P. 46–51. doi: 10.15585/mmwr.mm7002e1

[21] CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine: United States, December 14–23, 2020. Morb Mortal Wkly Rep. 2021;70(2):46–51. doi: 10.15585/mmwr.mm7002e1

[22] CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 Vaccine: United States, December 21, 2020–January 10, 2021. Morb Mortal Wkly Rep. 2021;70(4):125–129. doi: 10.15585/mmwr.mm7004e1

[23] CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 Vaccine: United States, December 21, 2020 January 10, 2021 // Morb Mortal Wkly Rep. 2021. Vol. 70, N 4. P. 125–129. doi: 10.15585/mmwr.mm7004e1

[24] CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 Vaccine: United States, December 21, 2020–January 10, 2021. Morb Mortal Wkly Rep. 2021;70(4):125–129. doi: 10.15585/mmwr.mm7004e1

[25] Somiya M, Mine S, Yasukawa K, Ikeda S. Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines. Vaccine. 2021;39(25):3313–3314. doi: 10.1016/j.vaccine.2021.04.066

[26] Somiya M., Mine S., Yasukawa K., Ikeda S. Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines // Vaccine. 2021. Vol. 39, N 25. P. 3313–3314. doi: 10.1016/j.vaccine.2021.04.066

[27] Somiya M, Mine S, Yasukawa K, Ikeda S. Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines. Vaccine. 2021;39(25):3313–3314. doi: 10.1016/j.vaccine.2021.04.066

[28] BioProcess International [Internet]. Maggio E. Polysorbates, biotherapeutics and anaphylaxis: A review [September 19, 2017]. Available from: https://bioprocessintl.com/manufacturing/formulation/polysorbates-biotherapeutics-and-anaphylaxis-a-review/. Accessed: 15.11.2023.

[29] BioProcess International [интернет]. Maggio E. Polysorbates, biotherapeutics and anaphylaxis: A review [September 19, 2017]. Режим доступа: https://bioprocessintl.com/manufacturing/formulation/polysorbates-biotherapeutics-and-anaphylaxis-a-review/. Дата обращения: 15.11.2023.

[30] BioProcess International [Internet]. Maggio E. Polysorbates, biotherapeutics and anaphylaxis: A review [September 19, 2017]. Available from: https://bioprocessintl.com/manufacturing/formulation/polysorbates-biotherapeutics-and-anaphylaxis-a-review/. Accessed: 15.11.2023.

[31] Coors EA, Seybold H, Merk HF, Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol. 2005;95(6):593–599. doi: 10.1016/S1081-1206(10)61024-1

[32] Coors E.A., Seybold H., Merk H.F., Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions // Ann Allergy Asthma Immunol. 2005. Vol. 95, N 6. P. 593–599. doi: 10.1016/S1081-1206(10)61024-1

[33] Coors EA, Seybold H, Merk HF, Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol. 2005;95(6):593–599. doi: 10.1016/S1081-1206(10)61024-1

[34] Zhao W, Zha X, Wang N, et al. Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: A retrospective cohort study. medRxiv. 2020. doi: 10.1101/2020.03.13.20035436

[35] Zhao W., Zha X., Wang N., et al. Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: A retrospective cohort study // medRxiv. 2020. doi: 10.1101/2020.03.13.20035436

[36] Zhao W, Zha X, Wang N, et al. Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: A retrospective cohort study. medRxiv. 2020. doi: 10.1101/2020.03.13.20035436

[37] Pumphrey RS, Roberts IS. Postmortem findings after fatal anaphylactic reactions. J Clin Pathol. 2000;53(4):273–276. doi: 10.1136/jcp.53.4.273

[38] Pumphrey R.S., Roberts I.S. Postmortem findings after fatal anaphylactic reactions // J Clin Pathol. 2000. Vol. 53, N 4. P. 273–276. doi: 10.1136/jcp.53.4.273

[39] Pumphrey RS, Roberts IS. Postmortem findings after fatal anaphylactic reactions. J Clin Pathol. 2000;53(4):273–276. doi: 10.1136/jcp.53.4.273

RIGHTS & PERMISSIONS

Eco-Vector